CATAPRES Tablet Ref.[6730] Active ingredients: Clonidine

Adults only

The usual initial dosage is 0.05 to 0.10 mg three times daily with subsequent gradual increments to the level of optimal control generally in the daily dose range of 0.3 to 1.2 mg in divided doses although higher levels may be required.

Should clonidine be added to other anti-hypertensive therapy dosage of the latter should be gradually reduced as the clonidine is introduced.

Patients undergoing anaesthesia should continue their Catapres treatment before, during and after anaesthesia using oral or intravenous administration according to individual circumstances.

Paediatric Population

There is insufficient evidence for the application of clonidine in children and adolescents younger than 18 years. Therefore the use of clonidine is not recommended in paediatric subjects under 18 years.

Renal insufficiency

Dosage must be adjusted:

• according to the individual antihypertensive response which can show high variability in patients with renal insufficiency
• according to the degree of renal impairment

Symptoms

Manifestations of intoxication are due to a generalised sympathetic depression and include pupillary constriction, lethargy, bradycardia, hypotension, hypothermia, somnolence including coma and respiratory depression including apnoea. Paradoxical hypertension caused by stimulation of peripheral alpha1-receptors may occur. Transient hypertension may be seen if the total dose is over 10mg.

Treatment

Gastric lavage should be performed where appropriate. In most cases all that is required are general supportive measures. Where bradycardia is severe atropine will increase the heart rate.

36 months.

Do not store above 30°C.

Keep the blisters in the outer carton.

Opaque PVC 250 μm/PVDC 40g/m² blisters with aluminium lidding foil 20 μm containing 50, 84, 100 or 250 tablets. Not all pack sizes are marketed.

No special requirements.